Results 1 to 10 of about 9,741 (153)

Prasugrel [PDF]

Circulation, 2010
N ...
Stephen D, Wiviott, Elliott M, Antman, Eugene, Braunwald   +2 more
doaj   +9 more sources

The efficacy and safety of prasugrel in acute coronary syndrome: a propensity-matched Korean cohort study focused on age and weight of patients. [PDF]

BMC Cardiovasc Disord
Background The clinical benefits of prasugrel compared to clopidogrel in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are well established.
Kim SH, Choo EH, Kang J, Lee JM, Yoo KD, Park MW, Park CS, Kim HY, Kim MC, Ahn Y, Chang K, Kim HS.   +11 more
europepmc   +2 more sources

Prasugrel

Expert Opinion on Investigational Drugs, 2006
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes.
Udaya S, Tantry, Kevin P, Bliden, Paul A, Gurbel   +2 more
europepmc   +5 more sources

Prasugrel [PDF]

Reactions Weekly, 2013
The unequivocal importance of platelet inhibition for prevention of secondary occlusive vascular events in patients with coronary heart disease is well established. Yet the scientific debates on the preferred agents for platelet inhibition have reached new heights.
Victor, Serebruany, Dan, Atar
  +7 more sources

Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. [PDF]

PLoS ONE, 2013
Administration of the thienopyridine P2Y12 receptor antagonist, clopidogrel, increased the erosive arthritis induced by peptidoglycan polysaccharide (PG-PS) in rats or by injection of the arthritogenic K/BxN serum in mice. To determine if the detrimental
Analia E Garcia, Mario C Rico, Elisabetta Liverani, Raul A DeLa Cadena, Paul F Bray, Satya P Kunapuli   +5 more
doaj   +1 more source

Early vs. Delayed Initiation of Treatment With P2Y12 Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Cardiovascular Medicine, 2022
AimsWhether early or delayed dual antiplatelet therapy initiation is better in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is unclear. We assessed the evidence for comparing the efficacy and safety of early vs. delayed P2Y12
Lourdes Vicent, Lourdes Vicent, Carlos Diaz-Arocutipa, Giuseppe Tarantini, Marco Mojoli, Adrian V. Hernandez, Adrian V. Hernandez, Héctor Bueno, Héctor Bueno, Héctor Bueno, Héctor Bueno   +10 more
doaj   +1 more source

Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.

PLoS ONE, 2022
BackgroundTriple antithrombotic therapy, including dual antiplatelet therapy and oral anticoagulant (OAC), is recommended for a short-term period after percutaneous coronary intervention (PCI) in patients requiring anticoagulation therapy. The purpose of
Hideki Kitahara, Kazuya Tateishi, Yuki Shiko, Yusuke Inaba, Yoshio Kobayashi, Takahiro Inoue   +5 more
doaj   +1 more source

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

Thrombosis Journal, 2020
Background Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y12 receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.
Ippei Ikushima, Takaaki Akasaka, Yoshiyuki Morishima, Atsushi Takita, Tomoko Motohashi, Tetsuya Kimura   +5 more
doaj   +1 more source

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention

Российский кардиологический журнал, 2020
Aim. To conduct a cost analysis of using novel inhibitors of P2Y 12 (prasugrel and ticagrelor) in patients with acute coronary syndrome (ACS) in the Russian healthcare system.Material and methods.
I. N. Dyakov, E. A. Ushkalova
doaj   +1 more source

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Journal of Interventional Cardiology, 2023
Background. Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial.
Amit Sachdeva, Ratnabhushan Mutyala, Neha Mantri, Shiyun Zhu, Edward McNulty, Matthew Solomon   +5 more
doaj   +1 more source